EcoDrugPlus

Adenosine A1 Receptor

Ensembl ID : ENSMZEG00005014987
Gene Symbol: ADORA1
3 Cross references
204 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSMZEG00005017671
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSMZEG00005002189
Gene Symbol: ADORA2A
3 Cross references
189 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSMZEG00005007221
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSMZEG00005003103
Gene Symbol: ADORA3
1 Cross references
135 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSMZEG00005023500
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1

Ensembl ID : ENSMZEG00005006459
Gene Symbol: LOC101484151
3 Cross references
173 Possible Orthologues:

Adenosine Receptor A3

Ensembl ID : ENSMZEG00005027147
Gene Symbol: LOC106674504
2 Cross references
39 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSMZEG00005025077
Gene Symbol: ADRA1B
3 Cross references
194 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSMZEG00005023624
Gene Symbol: ADRA1D
3 Cross references
194 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSMZEG00005002954
Gene Symbol: ADRA2A
3 Cross references
176 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSMZEG00005027507
Gene Symbol: ADRA2A
3 Cross references
159 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).